Financings in Brief: ESC Medical Systems
This article was originally published in The Gray Sheet
ESC Medical Systems: Firm completes a $115 mil. placement of 6% convertible subordinated notes due 2002. Proceeds from the offering -- which included exercise of a $15 mil. over-allotment option -- will be used for working capital and general corporate purposes, including possible acquisitions. The notes are convertible into the company's ordinary shares at a conversion price equal to $46.55 per share, the Yokneam, Israel-based dermatologic laser firm states ("The Gray Sheet" Sept. 15, p. 21)...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.